Effect of Methamphetamine Self-Administration on Neurotensin Systems of the Basal Ganglia

Paul S. Frankel, Amanda J. Hoonakker, Mario E. Alburges, Jacob W. McDougall, Lisa M. McFadden, Annette E. Fleckenstein and Glen R. Hanson

Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah

(PSF, AJH, MEA, JWM, LMM, GRH)
RUNNING TITLE PAGE

Running title: Effect of Methamphetamine Self Administration on Neurotensin

Corresponding Author:

Glen R. Hanson, Ph.D., D.D.S.
Room 112 Skaggs Hall
College of Pharmacy, University of Utah
Salt Lake City, UT 84112

Tel.: 801-581-3174
Fax: 801-585-5111
e-mail: glen.hanson@hsc.utah.edu

Text page number: 17
Table number: 0
Figure number: 5
Reference number: 33
Abstract word number: 240
Introduction word number: 712
Discussion word number: 1454

Nonstandard Abbreviations: METH, methamphetamine; SAM, self-administering methamphetamine; YM, yoked-methamphetamine; YS, yoked-saline; NT, neurotensin; DYN, dynorphin

Recommended section assignment: Neuropharmacology
ABSTRACT

Methamphetamine (METH) dependence causes alarming personal and social damage. Even though many of the problems associated with abuse of METH are related to its profound actions on dopamine (DA) basal ganglia systems, there currently are no approved medications to treat METH addiction. For this reason we and others have examined the METH-induced responses of neurotensin (NT) systems in the basal ganglia. This neuropeptide is associated with inhibitory feedback pathways to nigrostriatal DA projections and NT tissue levels are elevated in response to high doses of non-contingent METH because of its increased synthesis in the striatonigral pathway. The present study reports the contingent responses of NT in the basal ganglia to self-administration of METH (SAM). METH i.v. infusions linked to appropriate lever pressing by rats significantly elevated NT content in both dorsal striatum (210%) and substantia nigra (202%). In these same structures, NT levels were also elevated in yoked METH animals (160% and 146%, respectively), but not as much as in the SAM rats. These effects were blocked by a D1, but not D2, antagonist. A NT agonist administered prior to the 5th day of operant behavior blocked lever pressing in responding rats, but a NT antagonist had no significant effect on this behavior. These are the first reports that NT systems associated with striatonigral pathway are significantly altered during METH self-administration and our findings suggest that activation of NT receptors during maintenance of operant responding reduces the associated lever pressing.
INTRODUCTION

The personal and social damage caused by METH abuse/addiction (Meredith et al., 2005) is likely due, at least in part, to its profound actions on dopamine (DA) basal ganglia systems (Fleckenstein et al., 2007). However, there currently are no approved medications for these METH problems, including drugs with direct DA actions (Elkashelf et al., 2008). Consequently, it is important to research novel systems to develop effective medications to treat METH addiction. To this end, others and we have investigated the role of the neuropeptide, neurotensin (NT) in METH abuse models. Neurotensin is synthesized in dorsal striatal cell bodies and linked with the two major striatal efferent projections referred to as the direct (striatonigral) and indirect (striatopallidal) feedback pathways to the nigrostriatal DA neurons (Castel et al., 1994; Gerfen, 1990). This dual anatomical arrangement makes NT uniquely positioned to differentially regulate the basal ganglia DA pathway through either D1 (direct feedback pathway) or D2 (indirect feedback pathway) receptor mechanisms. Overall, activation of NT systems or receptors antagonizes DA activity (Chartoff et al., 2004; Feifel et al., 2008), with an apparent physiological role to counteract overactive DA pathways (Wagstaff et al., 1994), leading to the conclusion that NT is a natural neuroleptic and that NT agonists would be effective treatment for hyper-DA psychoses such as schizophrenia (Feifel et al., 2008; Hadden et al., 2005).

Study of the role of DA receptors in regulating NT systems has revealed that stimulation of D1 or D2 receptors have opposite effects, either increasing (selectively in striatonigral neurons; Castel et al. 1994) or decreasing (selectively in striatopallidal neurons; Castel et al. 1994; Merchant et al. 1989b) the NT tissue levels in the dorsal striatum, respectively. In
contrast, D1 receptor blockade alone has been reported to have no effect on dorsal striatal NT levels, but D2 receptor antagonism increases NT levels in striatopallidal neurons (Merchant et al., 1989a,b; Castel et al. 1994).

Much like D1 receptor activation, non-contingent high doses of METH (~10 mg/kg) also increase NT tissue levels as well as increase related mRNA expression in the dorsal striatum associated with striatonigral neurons (Castel et al. 1994; Merchant et al. 1994; Letter et al. 1987). These effects are blocked by pretreatment with SCH23390 (a D1 antagonist), but not eticlopride (a D2 antagonist) (Castel et al. 1994). These elevated NT tissue levels do not seem to be related to changes in NT release per se because 10 mg/kg of METH does not change either striatal or nigral extracellular NT levels as measured by microdialysis (Wagstaff et al., 1996a; Frankel et al., 2005). In contrast, stimulation of D2 receptors as mentioned above reduces NT levels in the dorsal striatum, an effect that likely reflects a significant release and turnover of NT (Wagstaff et al. 1994; Wagstaff et al. 1996b) causing a feedback inhibition that can be blocked by either central infusion of a selective NT antibody or antagonist thereby enhancing both the drug-induced DA and locomotor response (Wagstaff et al. 1994). A D2 antagonist has the opposite effects (Merchant et al. 1989a; Wagstaff et al. 1996b).

Although these types of non-contingent studies implicate NT systems in the immediate pharmacological effects of METH and its neurobiology, their relevance to human abuse is uncertain. For example, it is not clear under contingent conditions (i.e., METH access is linked to operant behavior) how NT systems are affected, and will a response be dominated by a (i) somewhat quiescent D1-dominated NT striatonigral feedback pathway or (ii) a D2-dominated active feedback inhibitory pathway? Such information is necessary to elucidate
the nature of NT’s role in METH use, and assess the therapeutic potential of this neuropeptide system.

In order to mimic more accurately the real-life situation of human psychostimulant abuse, the present study determined the response of NT systems to METH self-administration (contingent on appropriate lever pressing) paradigms. In these studies the contingent NT responses in rats were determined by comparing NT tissue levels in basal ganglia structures previously shown to be sensitive to investigator-administered METH treatments (Letter et al., 1987), during an abbreviated (5 d), but stable pattern (referred to as maintenance) of self-administration of METH (SAM) to those of yoked-METH (YM) and yoked-saline (YS) animals based on a modification of the operant-training method described by Fuchs et al. (2005) and See et al. (2007).
METHODS

Animals. Male Sprague-Dawley rats (300-350 gm; Charles River Laboratories, Raleigh, NC) were allowed to acclimate for at least 1 week prior to experimentation. For most studies, the rats to be used for self-administration were initially group-housed during food training (Fuchs et al., 2005) and then housed individually after catheter implantation. These rats were killed 6 h after the final 5th self-administration session. In the study represented in Fig. 1, the rats received a single non-contingent administration of 10 mg/kg METH, s.c. and were killed 12 h later. To study the effect of lever pressing for food, rats were exposed to either active levers that delivered a food pellet when appropriately pressed (food-trained rats) or to inactive levers (control rats). See the Food Training section in Material and Methods for more detail. These animals were also killed 6 h after the 4th daily session.

Drugs and Chemicals. Methamphetamine hydrochloride was furnished by the National Institute on Drug Abuse, National Institute of Health (Bethesda, MD) and infusion quantities were calculated as the free base. In the experiments to study the DA receptor mechanisms underlying the NT responses to contingent METH treatments, yoked-METH rats were pretreated by i.p injections of 0.5 mg/kg of either the D1 (SCH23390 from Research Biochemicals Inc.; \(R^+\)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride) or D2 (eticlopride from Research Biochemicals Inc.; \(S^-\)-3-chloro-5-ethyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-hydroxy-2-methoxybenzamide hydrochloride) receptor antagonists. This pretreatment has previously been used by us (Merchant et al. 1989b and Wagstaff et al. 1996a,b) and others (Beauvais et al. 2010; Castel et al. 1994) in non-contingent studies to determine the selective role of these two DA receptor
subtypes in the pharmacological actions of METH. These drugs were administered 15 min prior to each of the 5 METH self-administration sessions.

In a separate study, the effect of stimulating and blocking the NT receptors on METH SA was examined by administering a NT agonist (PD149163 [obtained from the National Institute of Mental Health, NIH]; a stable NT fragment (NT[8-13]) that stimulates CNS NT1 receptors when delivered systemically; 0.5 mg/kg, s.c.; Feifel et al. 2008) and antagonist (SR48692 [purchased from Tocris Bioscience; 0.3 mg/kg; Antonelli et al. 2007; Wagstaff et al. 1994] prior to the 5th (PD149163) or 5-7th (SR48692) d of METH SA. Follow-up studies suggested that PD149163 alone did not impair motor functions because the performance of rats on the rotor rod, treated with this NT agonist, was identical to saline-treated animals at rpms of 6, 9 and 12 (i.e., no falls from the rotating rod regardless of rpm rate; n=6 rats). We observed that eating behavior of both saline- and PD149163-treated rats after returned to their home cage following the session were identical (note: during these sessions, both groups gained an average of 10-20 gms on this feeding regimen). In addition, the observation that the PD compound alone did not increase motor behavior like METH administrations suggests that NT agonists are not stimulants and do not have pharmacological properties like METH. This is consistent with previous reports that: (1) pretreatment with icv NT blocks stimulant (including amphetamine)-induced locomotion (Norman et al. 2008); (2) NT receptor stimulation blocks stimulant-induced DA release (Liang et al. 2008); and (3) NT receptor knockouts have hyperactivity (Liang et al. 2010).

**Food Training:** Because we have observed that in our treatment paradigm, food training predicted an animal’s ability to acquire drug self-administration, all rats used were required to pass food training as described previously (Fuchs et al., 2005; See et al., 2007). Briefly,
rats were restricted to approximately 85% of their free-feeding food quantity, and then placed in Coulbourn operant chambers connected to a PC computer running Graphic State software. Each chamber was equipped with two retractable levers, a food pellet dispenser between the levers, and a house light on the wall opposite the levers. One lever was the “active” lever resulting in the delivery of a food pellet while the other lever had no programmed consequences. Training consisted of a schedule of food reinforcement (45 mg Rodent Grain food pellets; Bio-Serv Delivering Solutions) FR 1 with only the stimulus-appropriate (drug-lever) eliciting the reward. If, during the overnight food-training session (15 h) a rat received 50 pellets, the FR was increased to 2. If the rat obtained another 50 food pellets, the FR increased to 3 for the balance of the session. Rats remained in the food-training phase for either 4 days or until they achieved 2 consecutive sessions on the FR 3 schedule after which they received a jugular vein catheter implant (~90% of the rats successfully completed food training and on average press the active lever from 800-1000 times during the final session).

**Catheter implantation:** After food training, rats were anesthetized with Equithesin (i.p.) and indwelling catheters consisting of a screw-type connector, silastic tubing (10 cm i.d., 0.64 mm o.d., 1.19 mm) Prolite polypropylene monofilament mesh and cranioplastic cement were implanted beneath the skin of the back (at the shoulder-blades). The outlet of the catheter ran subcutaneously around the underside of the animal with the end inserted into the right jugular vein. The catheter was secured to the surrounding tissue with sutures. A 0.1-ml antibiotic solution contained Cefazolin (10.0 mg/ml) dissolved in heparinized saline (70 U/ml; Sigma, St Louis, MO) was flushed through the catheter for 3 days after surgery to extend catheter patency. Thereafter, catheters were flushed with 0.1 ml of heparinized saline before and after each self-administration session to prevent clotting (Frankel et al., 2008). Styles were
inserted into the catheters when rats were not connected to infusion pumps. All experiments were approved by the University of Utah Institutional Animal Care and Use Committee and adhered to the National Academy of Sciences ‘Guide for the Care and Use of Laboratory Animals.

**METH Self-administration Training.** Operant training was based on procedures as previously described (Fuchs et al., 2005; See et al., 2007). Self-administration sessions were conducted during the light cycle; however, animals were exposed to a 14/10 h light/dark environment while in their home cages. Each SAM rat underwent 4-h sessions in Coulbourn operant chambers for 5 consecutive days and were exposed to the presentation of an identical right and left lever. One of the levers was selected as active such that appropriate pressing resulted in a primary stimulus of METH infusion (0.06 mg/infusion) followed by lever retraction for a 20-second time-out period until subsequent presentation of the levers. The SAM rats selectively pressed the active lever >90% of the time. Data collection and reinforcer delivery was controlled by a PC computer using Graphic State Notation (Coulbourn Instruments). Prior to initiation of self-administration training, each SAM rat was randomly paired with two yoked rats. The yoked animals were prepared and treated identically as the SAM animals except that both levers in the operant chamber had no programmed consequences. Furthermore, these yoked animals received either METH (0.06 mg/infusion; YM) or saline (equal volume; YS) at times determined by the behavior of the SAM rats. After each self-administration session, all rats were returned to their home cages and given access to 6 gms of Purina rat chow. After 1 day of METH self-administration at an FR 1, the FR was increased within the session to an FR 2 after 25 presses, an FR 3 after 30 presses and finally an FR 5 after 45 presses (rats typically reached the FR 5 stage toward the
conclusion of the 2nd session of acquisition and remained throughout the remainder of the study). For these studies, SAM rats were considered to have reached criterion if they maintained at least 3 consecutive days of relatively steady lever pressing (with at least 0.6 mg/kg/day METH infusions and self-administered a total of at least 3 mg of i.v. METH for the experiment; this was typical of 80% of our SAM animals). Six hours after the 5th self-administration session, the rats were killed, brains removed and frozen on dry ice.

**Analysis of Neuropeptide Levels in Tissue:** Levels of NT, dynorphin (DYN) and metenkephalin were determined by specific and sensitive RIAs previously described (Frankel et al., 2007). The striatum and the substantia nigra were dissected (Paxinos and Watson, 1982) and frozen at -80℃ until assayed for the appropriate neuropeptide. Typical striatal peptide levels (pg/mg protein) in control animals were 110 (Fig. 1) and 78 (Fig. 5) for NT and DYN, respectively; typical nigral peptide levels (pg/mg protein) in control animals were 331 (Fig. 1) and 231 (Fig. 5), respectively. To facilitate comparisons, data were normalized by dividing with respective control mean values and expressed as percent of control.

**Statistical Analysis:** The data presented are means + standard error of the mean (S.E.M.). All data were analyzed using SAS 9.1 (SAS Institute, Cary, NC, USA). For analysis of NT and DYN levels, three or more groups were compared by one-way analysis of variance followed by a Newman-Keuls post hoc test or Student’s t-test. Two groups were assessed using a t-test. Pressing behaviors were analyzed using a repeated measures ANOVA. A test of sphericity was performed on repeated measures factors to ensure symmetry of the variance–covariance matrix. The Huynh-Feldt correction was used for any matrices that were significantly non-spherical. All results, were considered significant when p<0.05.
RESULTS

Rats that received saline infusions (YS), averaged 19±12 lever presses on what had been the active lever for food training, during their first session of being yoked to SAM animals. The average lever-pressing behavior dropped off to 4-5±3 presses/session for the 4th and 5th sessions prior to sacrificing. For the SAM rats the pattern of lever pressing from days 1-4 is shown in Fig. 4 (note: rats used for Figs 2 and 3 had 5 days of self-administration with the lever-pressing patterns for days 1-4 similar to that shown in Fig. 4 and the 5th day activity=38± 3 pushes). Notable is the finding that the SAM animals maintained a relatively stable pattern of METH self administration for sessions 3-5.

In order to assess the METH-induced responses of NT systems associated with the basal ganglia, the tissue levels of this neuropeptide were measured in the dorsal striatum of rats which non-contingently received 1 s.c. injection of METH (10 mg/kg/administration). As previously reported (Letter et al., 1987), investigator-administered METH increased the striatal level of NT (t(11)=3.22, p<0.01; Fig. 1). To compare this METH effect with that in rats which self-administered this stimulant, NT levels of the striatum were measured in animals that received i.v. METH infusions in response to appropriate lever pressing (labeled contingent SAM in Fig. 1). As with the non-contingent drug treatment, NT tissue content in the SAM animals was significantly elevated vs. YS animals (F(2,25)=24.76, p<0.001). A similar, but significantly less increase in striatal NT levels was also found in the corresponding YM group. In order to confirm that the changes in striatal NT levels were due to exposure to METH and not because of food training itself, we measured NT levels in the striatum of rats killed 6 h following the final session of food training. We observed that
animals exposed to food training (61 ± 8 striatal NT pg/mg protein) vs those that were exposed to inactive levers (91 ± 7 striatal NT pg/mg protein) did not manifest an increase, but rather a decrease, in striatal NT levels (t(14)=2.26, p<0.05), confirming that the elevation in NT levels in SAM and YM rats was related to the METH exposure and not food training per se.

We next investigated the mechanism underlying the effect of METH self-administration on striatal NT systems (Fig. 2). Because it has been reported that the lever-pressing behavior of rats self-administering METH or related drugs is altered by D1 and D2 antagonists (Brennan et al. 2009), we avoided this confound by employing an indirect approach for these studies: this was done by pretreating the YM rats with either a D1 (SCH23390) or D2 (eticlopride) antagonist prior to each of the 5 sessions of METH infusions which were determined by the lever-pressing behavior of linked SAM animals. As demonstrated in Fig. 1, we again observed elevated NT levels in both SAM+Sal and YM+Sal rats (F(6,71)=51.07, p<0.001), which had been pretreated with saline, with the effect in the SAM group being greater. The YM effect compared to the YS group was blocked by a SCH23390 pretreatment. In contrast, the eticlopride pretreatment itself elevated striatal NT content (YS+etic), an effect that was additive with the METH-induced increase (YM + etic). These findings suggest that D1, but not D2, receptors are involved with the effects caused by METH self-administration on the dorsal striatal NT systems.

Because the findings in Fig. 2 suggested that the NT response to METH self-administration was D1-mediated, it is possible that the D1-dependent striatonigral pathway played an important role in this response. To test this possibility, we also examined NT levels in the substantia nigra (Fig. 3) in a manner similar to that described above for Fig. 2. As with
the striatal NT response, we observed that nigral NT levels were also increased in both the SAM and YM rats compared to the YS animals (F(6,94)=15.68, p<0.001), with the effects being greater in the SAM tissues. Also similar to the striatal responses, the results revealed that the nigral NT changes in the YM vs. YS rats were prevented by D1, but not D2, receptor antagonism. In contrast to the striatal response, eticlopride alone had no significant effect on nigral NT content thereby supporting the conclusion that the striatonigral NT system is particularly linked to D1, and not D2, systems.

While these findings demonstrate that basal ganglia NT pathways are altered by METH self-administration through D1 mechanisms, they do not provide much insight as to the functional significance of these elevations in NT tissue levels. To this end we determined the consequence of either activating or blocking the NT receptor on the level-pressing activity of SAM rats (Fig. 4). This was achieved by administration of either a NT receptor agonist (PD149163) or antagonist (SR48692) 15 min prior to placement of SAM rats into their respective operant chambers on either the 5th or 5th-7th d of METH self-administration, respectively. Stimulation of NT receptors on the 5th d reduced pressing by the SAM rats on the active lever from 39±5 to 6±3, while blockade of these receptors had no significant effects on lever pressing behavior in SAM rats on days 5-7 (F(6, 72)=4.84, p<0.001).

Finally, in order to test the selectivity of the NT response to METH self-administration, we measured the effect of this contingent behavior on the basal ganglia tissue levels of DYN and metenkephalin. These are neuropeptides that are selectively associated with either the D1-related striatonigral pathway (Jiang et al. 1990) or the D2-related striatopallidal pathway (Durieux et al. 2009), respectively, and we determined their striatal and nigral content in SAM, YM and YS rats (Fig. 5). The DYN content in both the striatum and substantia nigra
was elevated in SAM rats (striatum: F(2,26)=15.16, p<0.001; substantia nigra: F(2,25)=8.77, 
p<0.01). In the substantia nigra the DYN levels were also elevated in the YM animals. In 
contrast, no significant changes were observed in the striatal metenkephalin levels of either 
SAM or YM rats (F(2,24)=1.00, ns), data not shown.
DISCUSSION

Neurotensin in the basal ganglia is associated with striatal medium spiny efferent neurons that project to both the substantia nigra and globus pallidus (Castel et al., 1994; Gerfen et al., 1990) and likely contributes to the regulation of DA-related basal ganglia function. Although little is known about its precise role, studies have suggested that NT has an inhibitory influence on the stimulatory behavioral effects of psychostimulants (Feifel et al., 2008; Chartoff et al. 2004; Wagstaff et al., 1994), possibly through an indirect mechanism involving increased striatal GABA activity and subsequent reduced DA release (Ferraro et al., 1998). This inhibitory action has been speculated to be of potential clinical value suggesting that activation of NT receptors may have a neuroleptic action and be useful in the management of conditions of excessive DA activity (Feifel et al., 2008; Chartoff et al., 2004).

While the role of NT in regulating striatal DA function requires further elucidation, more is known about how changes in DA activity influence the striatal efferent NT systems. These studies have identified variations in striatal and nigral NT levels in response to activation of DA receptors either directly by selective agonists (Merchant et al., 1989a,b) or indirectly by psychostimulants such as METH (Letter et al., 1987). This research has found that stimulation of D1 receptors or administration of high doses of METH elevates tissue levels of NT in the striatum and substantia nigra. In contrast, activation of the D-2 receptor with a selective agonist or administration of a low dose of METH decreases striatal neurotensin content (Wagstaff et al., 1996; Merchant et al., 1989b).
Dopamine-related changes in the NT systems of the basal ganglia have also been monitored by assessing the synthesis of this neuropeptide through measurements of expression for the mRNA of its NT/neuromedin N precursor. Such studies demonstrated that changes in DA receptor activity caused by either selective direct D1-receptor agonists or indirect agonists such as METH, significantly increase the levels of striatal NT mRNA and the elevated synthesis likely contributes to increases in the associated NT tissue content (Hanson and Keefe, 1999; Castel et al., 1994).

Taken together, these studies suggest that activation of D1 receptors either by a selective D1 agonist or a high dose of METH, influences NT signaling and synthesis, increasing tissue accumulation of this peptide. In contrast, D2 receptor activation appears to have an opposite effect (i.e., it decreases striatal NT content). To appreciate better the interaction between basal ganglia NT and DA systems especially after METH administration, it is necessary to identify how the actual release of NT is affected by METH treatment. To this end, Wagstaff et al. (1996a,b) and Frankel et al. (2005) reported that NT release is increased in striatum and substantia nigra after a low, but not after the high METH dose that is required to elevate striatal NT levels. Taken together these findings suggest that investigator-controlled administration of METH high doses does not change NT release patterns per se, but does increase synthesis and levels of NT in the striatonigral pathway.

As previously mentioned, until the present report, all studies of METH-induced NT changes in the basal ganglia have been based on non-contingent models. As described above, others and we have elucidated many of the elements of this interaction; however, while these findings have helped us to better understand the pharmacology of this potent stimulant, their link to the critical issues related to human abuse is unclear. Thus, the relevance of these NT...
responses to important drug dependence elements such as drug wanting, anticipation, contingent administration and extinction are unknown. The design of the present METH self-administration study was intended to begin addressing these important questions. As described in results, the rats behaved as expected in that animals previously food-trained manifested lever pressing extinction very quickly once placed in the operant chambers when their learned operant behavior no longer was associated with a reward nor any consequence. It was also observed that those SAM rats which received METH infusions contingent to appropriate operant responding, stably lever pressed to receive a consistent daily dose of METH/session during the final 3 d of self-administration.

The data in Fig. 1 validate previous reports that the immediate pharmacology of high doses of non-contingently administered METH increases NT levels in basal ganglia areas (Letter et al., 1987). In addition, they extend this well-established finding to suggest that these NT systems are associated with elements of METH self-administration and might contribute to basal ganglia functions such as the transferring and processing of information in motor, cognitive and limbic domains associated with reward-related activity (Tisch et al., 2004). In particular, the finding that changes in striatal and nigral NT systems were greater in METH self-administering (SAM) rats than the corresponding yoked METH animals (YM) suggest that these NT systems are somehow linked to altered DA activities in the respective systems related to learning a response to the positive reinforcer METH.

The fact that METH self-administration elevated dorsal striatal NT levels suggested that the mechanism for this NT response was activation of D1 receptors due to METH-induced release of DA associated with the nigrostriatal pathway (Castel et al., 1994). This possibility was tested by pretreating rats prior to METH exposure with either a D1 (SCH23390) or a D2
(eticlopride) antagonist. Because it has been reported that D1 and D2 antagonists alter the lever pressing pattern (and consequently the amount of METH administered) in SAM animals (Brennan et al. 2009), we administered the antagonists prior to the sessions for the YM group to avoid this confound. The results in Fig. 2 supported the hypothesis that the striatal NT effects were mediated by D1, and not D2, receptors. Because previous non-contingent studies demonstrated that D1-mediated elevation in striatal NT tissue content is due to activation of NT synthesis and apparently not associated with release of NT per se (Castel et al. 1994; Wagstaff et al. 1996a), we tested if this was true in our self-administration model. This was accomplished by determining the lever-pressing pattern of SAM animals that were pretreated with either a NT agonist or antagonist on the 5th or 5th-7th day(s) of self-administering METH, respectively (Fig. 4). We found that stimulation of NT receptors with the PD149163 almost completely eliminated lever pressing. While lever pressing was still diminished the next day, it returned to normal levels by day 7. This confirmed conclusions by other investigators, and us that activation of this NT system has a general inhibitory influence on METH-mediated behaviors that have a DA basis and we now know that this likely includes some factors that are associated with drug self-administration (Wagstaff et al. 1994; Feifel et al. 2008; Nicola 2007). Pretreatment with the NT antagonist (SR48692) prior to days 5-7 enabled us to assess the state of endogenous NT release during METH self-administration. Because blockade of the NT receptor did not significantly alter the lever-pressing behavior of the SAM rats, we conclude that NT release did not influence the METH self-administration patterns under these conditions. This finding suggests that like high doses of METH, the D1-mediated elevation in NT tissue levels observed in SAM rats did not
reflect changes in NT release and are most likely due to an increase in NT mRNA expression as discussed above.

Another conclusion that is implied by these findings is that the NT system primarily responsible for these effects of METH self-administration is likely associated with the striatonigral pathway because of the dominant D1 linkage with this efferent projection. This was confirmed by the finding that nigral NT levels were elevated in both SAM and YM rats, with the SAM effect being greater, and that this response was also selectively blocked in the YM rats by pretreatment with SCH23390, but not eticlopride (see Fig. 3). In addition, our observation that METH self-administration elevated striatal and nigral DYN (Fig. 5), but not striatal metenkephalin, levels may be due to a selective action on the striatonigral, but not the striatopallidal, pathways.

In summary, the present findings support the hypothesis that the striatonigral NT system is involved in mediating responses to METH self-administration and may contribute to elements that influence METH dependence. In addition, these somewhat selective NT responses appear to be specifically associated with increases in D1 receptor activity related to the striatonigral pathway and confirm the relevance of much of the previous non-contingent METH studies to issues of dependence and addiction. Finally, under these circumstances, the increases in NT tissue levels during METH self-administration do not appear to be related to an increase in NT release due to our observation that a NT antagonist does not significantly alter lever pressing in the SAM animals, even though stimulation of the NT receptor with an agonist suppresses this operant behavior in these animals.
AUTHORSHIP CONTRIBUTIONS

Participated in research design: Frankel, Hoonakker, Alburges, McFadden, Fleckenstein, and Hanson

Conducted experiments: Frankel, Hoonakker, Alburges, and McDougall

Contributed new reagents or analytical tools: non

Performed data analysis: Frankel, Hoonakker, McFadden, and Hanson

Wrote or contributed to the writing of the manuscript: McFadden, Fleckenstein, and Hanson
REFERENCES


Wagstaff JD, Gibb JW, Hanson GR (1996b) Dopamine D2-receptors regulate neurotensin release from nucleus accumbens and striatum as measured by in vivo microdialysis. *Brain Res.* **721**:196-203.
FOOTNOTE:

This study was supported by Public Health Service Grants DA04222, DA00378, DA13367, DA11369 and DA019447.
LEGENDS FOR FIGURES

Fig. 1. METH-induced increases in the NT levels of the striatum after both non-contingent and contingent drug treatment. The non-contingent rats received 1 METH injection (10 mg/kg/injection of METH or saline, s.c.) and were sacrificed 12 h after treatment. In contrast, the contingent SAM and YM rats received >3.0 mg i.v. of METH over 5 sessions in the operant chambers and were killed 6 h after the final session. Values represent the mean percents of respective controls (Saline or YS) +S.E.M (N=7-10). *P<0.05 vs. respective saline or YS and YM. **P<0.05 vs. YS.

Fig. 2. METH-induced increases in striatal NT content of Yoked-METH (YM) vs. Yoked-Saline (YS) rats were blocked by pretreatment with the D1 (SCH; SCH23390), but not D2 (Etic; eticlopride), antagonist. Exposure to patterns of METH i.v. infusions (YM), identical to that determined by a yoked animal self-administering METH (SAM), significantly elevated the NT content but not as much as in the corresponding SAM animals. The eticlopride treatment in YS rats elevated NT levels in this brain region. These two treatments together had an additive effect on the NT response (YM+Etic). N=7-17. Values represent mean percents of YS +S.E.M. *P<0.05 vs. all other groups and each other.

Fig. 3. METH-induced increases in nigral NT of Yoked-METH (YM) vs. Yoked-Saline (YS) rats were blocked by pretreatment with the D1 (Sch; Sch23390), but not D2 (Etic; eticlopride), antagonist. Exposure to patterns of i.v. METH infusions (YM), identical to that determined by a yoked animal self-administering METH (SAM), significantly elevated the
nigral NT content but not as much as in the corresponding SAM animals. Values represent mean percents of YS ±S.E.M (N=7-16). * P<0.05 vs. all other groups. **P<0.05 vs. all other groups, but not each other.

**Fig. 4.** Effect of pretreatment with the NT agonist, PD149163 (PD), or antagonist, SR48692 (SR) on lever pressing in SAM rats. The PD compound was administered 15 min prior to the 5th session (N=7), while the SR compound was administered 15 min before each of sessions 5-7 (N=8). Activation of NT receptors significantly, but temporarily, reduced lever pressing vs. that which occurred on the 4th d of self-administration (*P<0.05) (N=15); however, blockade of NT receptors had no significant impact.

**Fig. 5.** Effect of METH self-administration on striatal and nigral dynorphin levels. Increases in striatal and nigral DYN were observed in SAM rats, but in YM animals a significant elevation only occurred in the substantia nigra. *P<0.05 vs. YS and YM in the striatum and vs. YS in the substantia nigra (N=9-10).
Figure 1
Figure 2

Striatal NT levels (% control)

YS  SAM  YM  YS+ Etic  YM+ Etic  YS+ SCH  YM+ SCH
Figure 3
Figure 4
Fig. 5

Dynorphin levels (% control)

YS       SAM     YM              YS     SAM    YM

* *

Fig. 5